Search - tctmd.com

Displaying 1 - 20 of 86

Sort: Relevancy | Date

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

News Daily News

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Michael O'Riordan

December 22, 2022

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Aortic Aneurysm Killed Soccer Journalist Grant Wahl, Wife Says

L.A. McKeown

December 14, 2022

News Daily News

Big Tobacco Scores a Win Against Graphic Warning Labels on Cigarette Packs

Michael O'Riordan

December 13, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

FDA: Endologix AAA Grafts Get New Labeling That Addresses Endoleak Potential

L.A. McKeown

December 06, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

Caitlin E. Cox

December 01, 2022

News Daily News

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Michael O'Riordan

November 22, 2022

News Daily News

Age-Related Macular Degeneration Linked to Severe Vascular Disease

Caitlin E. Cox

November 18, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

Todd Neale

November 16, 2022

News Daily News

New Risk Models Superior to Pretest Probability at Predicting CAD

Yael L. Maxwell

November 15, 2022

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Opinion CV Team Dispatch

November 2022 News Roundup

L.A. McKeown

November 01, 2022

Advertisement

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

The Biggest News of 2022: TCTMD’s Top 10

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Aortic Aneurysm Killed Soccer Journalist Grant Wahl, Wife Says

Big Tobacco Scores a Win Against Graphic Warning Labels on Cigarette Packs

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

FDA: Endologix AAA Grafts Get New Labeling That Addresses Endoleak Potential

TCTMD’s Top 10 Most Popular Stories for November 2022

Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis

Age-Related Macular Degeneration Linked to Severe Vascular Disease

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

New Risk Models Superior to Pretest Probability at Predicting CAD

Many STEMI Patients Not Treated Within National Time Goals

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 2022 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content